Du Xinwen, Huang Xuan, Feng Xianqiong, Shui Yuping, Zhang Aihua, Li Jialing, Qiu Chujin, Wang Guan
Department of Hematology, Department of Operating Room, Department of Neurosurgery, Cancer Center, Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, 610041, China.
Breast Cancer Res Treat. 2025 Jan;209(1):39-48. doi: 10.1007/s10549-024-07468-7. Epub 2024 Aug 23.
To evaluate the application effects of The-Optimal-Lymph-Flow IT System in Chinese patients at high risk of developing breast cancer-related lymphedema.
A total of 104 breast cancer patients were randomly assigned to either the control group or the intervention group. The intervention group was provided with the The-Optimal-Lymph-Flow program, while the control group received the usual care. Trial outcomes including symptom experience, quality of life, and limb volume were evaluated at baseline, and at end of the 1- and 3-month trials.
After controlling for covariates, the incidence of eight symptoms was significantly higher in the control group than in the intervention group. There were significant differences in the changes in the severity of symptoms and arm volume between the two groups from baseline to 3 months after the intervention.
The application of TOLF in patients at high risk of developing lymphedema following breast cancer treatment significantly improved the lymphedema-related symptoms experienced in the early stage after surgery. Trial registration ChiCTR1800016713.
评估最优淋巴引流IT系统在中国乳腺癌相关淋巴水肿高危患者中的应用效果。
总共104例乳腺癌患者被随机分配到对照组或干预组。干预组接受最优淋巴引流方案，而对照组接受常规护理。在基线时以及1个月和3个月试验结束时评估包括症状体验、生活质量和肢体体积在内的试验结果。
在控制协变量后，对照组8种症状的发生率显著高于干预组。两组从基线到干预后3个月症状严重程度和手臂体积的变化存在显著差异。
最优淋巴引流方案在乳腺癌治疗后淋巴水肿高危患者中的应用显著改善了术后早期出现的与淋巴水肿相关的症状。试验注册号：ChiCTR1800016713。
